Status | Study |
Terminated |
Study Name: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Condition: Giant Cell Tumor of Bone Osteoclastoma Date: 2009-04-28 Interventions: Drug: Zoledronic acid 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year aft |
Active, not recruiting |
Study Name: Study of Denosumab in Subjects With Giant Cell Tumor of Bone Condition: Cancer GCT Giant Cell Tumor o Date: 2008-05-15 Interventions: Drug: Denosumab 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 m |
Completed |
Study Name: Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Condition: Cancer Date: 2007-10-01 Interventions: Drug: Fentanyl sublingual spray |
Completed |
Study Name: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Condition: Cancer Date: 2007-07-10 Interventions: Drug: cyclophosphamide Other: laboratory b |
Active, not recruiting |
Study Name: Trial of Dasatinib in Advanced Sarcomas Condition: Rhabdomyosarcoma Malignant Peripheral Nerve Sheath Tumors Date: 2007-04-20 Interventions: Drug: Dasatinib oral agent, continuous dosing, Cycles = 28 days |
Completed |
Study Name: Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone Condition: GCT Giant Cell Tumor of Bone Date: 2006-11-02 Interventions: Biological: Denosumab Administ |